27
Participants
Start Date
March 31, 2003
Primary Completion Date
November 30, 2009
Study Completion Date
November 30, 2009
Campath-1H
3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
G-CSF
10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
GM-CSF
250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
BCNU
300 mg/m2 IV over 1 hour on day -6
Stem Cell Transplant
Stem cell infusion on Day 0.
Preparative Regimen for Allogenic Stem Cell Transplantation
Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
Cytarabine
200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
Etoposide
200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
Melphalan
140 mg/m2 IV on day -1.
Campath
15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
Fludarabine
30 mg/m2 IV/day (days -6 to -4)
Cyclophosphamide
750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
Low dose total body irradiation
Low dose total body irradiation of 2 Gy day 0.
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Bayer
INDUSTRY
M.D. Anderson Cancer Center
OTHER